Press Oliver A, Guzman Roberta, Cervantes Monica, Santiago Angela, Press Michael F
Department of Pathology, USC Keck School of Medicine, Los Angeles, CA, USA.
Methods Mol Biol. 2014;1180:181-207. doi: 10.1007/978-1-4939-1050-2_10.
The use of human epidermal growth factor receptor type 2 (HER2) gene amplification and overexpression as a molecular predictive marker has become critically important for proper selection of breast cancer patients for treatment with targeted therapeutic agents such as trastuzumab, lapatinib, pertuzumab, and T-DM1. A high level of sensitivity and specificity of molecular tests for this alteration is desirable. The American Society of Clinical Oncology and College of American Pathology have jointly established consensus guidelines to standardize characterization of this alteration in breast cancers. This chapter provides a brief overview of pre-analytic and analytical processing of breast specimens as well as subsequent molecular evaluation for HER2 status.
将人表皮生长因子受体2（HER2）基因扩增和过表达用作分子预测标志物，对于正确选择乳腺癌患者使用曲妥珠单抗、拉帕替尼、帕妥珠单抗和T-DM1等靶向治疗药物进行治疗至关重要。对于这种改变的分子检测，需要具有高度的敏感性和特异性。美国临床肿瘤学会和美国病理学家学会联合制定了共识指南，以规范乳腺癌中这种改变的特征描述。本章简要概述了乳腺标本的分析前和分析处理，以及随后对HER2状态的分子评估。
